What is the most expensive pharmaceutical drug in the world?
Table of Contents
What is the most expensive pharmaceutical drug in the world?
1. Zolgensma (API Onasemnogene abeparvovec-xioi) In May 2019, FDA approved new gene therapy for SMA, and with the price tag of $2,125,000, it’s the most expensive drug the world has ever seen.
Why are Zolgensma prices so high?
Zolgensma is the second and most effective drug for the disorder. The reason for its exorbitant cost is its miniscule market size in the drug manufacturing industry and its potential to save lives. “The disorder is rare and that is why we needed a highly specialized drug.
What is the most expensive medication in the US?
1) Zolgensma – $2,125,000 Since Zolgensma received FDA approval in May 2019, it has remained the most expensive drug in the U.S., with a one-time cost of $2.1 million for a course of treatment.
How long does it take for Zolgensma to work?
How long does it take to work? Zolgensma starts working to treat SMA as soon as it’s injected. In clinical studies of the drug, some children saw improvements in their SMA symptoms as early as 1 month after they received the drug.
What is the most popular pharmaceutical drug?
What are the Most Prescribed Drugs in America?
| Drug Name | Total U.S. Patients (2019) | Brand Name |
|---|---|---|
| Atorvastatin | 24,493,971 | Lipitor |
| Amoxicillin | 20,368,921 | Amoxil, Trimox |
| Lisinopril | 19,990,170 | Prinivil, Zestril |
| Levothyroxine | 19,698,087 | Synthroid, Levoxyl |
What is the most expensive medication for rheumatoid arthritis?
Humira. Humira, used to treat Crohn’s disease and rheumatoid arthritis, tops the list of expensive brand drugs with cash prices averaging $9,065 per month.
Is Zolgensma approved in Germany?
Zolgensma Loses Orphan Benefit in Germany After ‘Very High Sales’ Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.
What does Zolgensma cure?
Zolgensma is approved to treat spinal muscular atrophy (SMA)* in children less than 2 years old. The SMA must be caused by genetic changes in the SMN1 gene. This gene is in nerve cells and helps control muscle function. Zolgensma contains the active ingredient onasemnogene abeparvovec.
When was Zolgensma released?
Zolgensma was approved by the FDA, under a priority review, on May 24, 2019, as a one-time IV treatment for people with any type of SMA up to age 2.